4.7 Article

Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease

Journal

ANNALS OF NEUROLOGY
Volume 73, Issue 4, Pages 554-559

Publisher

WILEY-BLACKWELL
DOI: 10.1002/ana.23817

Keywords

-

Funding

  1. Australian Research Council
  2. Australian National Health and Medical Research Council
  3. CRC for Mental Health
  4. Victorian State Government
  5. University of Melbourne
  6. Mental Health Research Institute
  7. Alfred Hospital
  8. Victorian Forensic Institute of Medicine
  9. Neurosciences Australia
  10. National Health and Medical Research Council

Ask authors/readers for more resources

Ceruloplasmin is an iron-export ferroxidase that is abundant in plasma and also expressed in glia. We found a approximate to 80% loss of ceruloplasmin ferroxidase activity in the substantia nigra of idiopathic Parkinson disease (PD) cases, which could contribute to the pro-oxidant iron accumulation that characterizes the pathology. Consistent with a role for ceruloplasmin in PD etiopathogenesis, ceruloplasmin knockout mice developed parkinsonism that was rescued by iron chelation. Additionally, peripheral infusion of ceruloplasmin attenuated neurodegeneration and nigral iron elevation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model for PD. These findings show, in principle, that intravenous ceruloplasmin may have therapeutic potential in PD. Ann Neurol 2013;73:554-559

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available